Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.

نویسندگان

  • Tobias Karlberg
  • Martin Hammarström
  • Patrick Schütz
  • Linda Svensson
  • Herwig Schüler
چکیده

Poly-ADP-ribose polymerases (PARPs) catalyze transfer of ADP-ribose from NAD(+) to specific residues in their substrate proteins or to growing ADP-ribose chains. PARP activity is involved in processes such as chromatin remodeling, transcription control, and DNA repair. Inhibitors of PARP activity may be useful in cancer therapy. PARP2 is the family member that is most similar to PARP1, and the two can act together as heterodimers. We used X-ray crystallography to determine two structures of the catalytic domain of human PARP2: the complexes with PARP inhibitors 3-aminobenzamide and ABT-888. These results contribute to our understanding of structural features and compound properties that can be employed to develop selective inhibitors of human ADP-ribosyltransferases.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2

The poly(ADP-ribose) polymerase (PARP) family represents a new class of therapeutic targets with diverse potential disease indications. PARP1 and PARP2 inhibitors have been developed for breast and ovarian tumors manifesting double-stranded DNA-repair defects, whereas tankyrase 1 and 2 (TNKS1 and TNKS2, also known as PARP5a and PARP5b, respectively) inhibitors have been developed for tumors wit...

متن کامل

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Small-molecule inhibitors of PARP are thought to mediate their antitumor effects as catalytic inhibitors that block repair of DNA single-strand breaks (SSB). However, the mechanism of action of PARP inhibitors with regard to their effects in cancer cells is not fully understood. In this study, we show that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA. Trapped PARP-DNA complex...

متن کامل

Inhibits endogenous poly-ADP-ribosyltransferases often present in membrane preparations with minimal effect of bacterial toxin mediated ADP-ribosylation. Inhibits nitric oxide-induced apoptosis but not/ differentiation in HL-60 cells. Protects cells from oxygen radical and nitric oxide toxicity. Inhibits stressinduced apoptosis

ABT-888 is a potent, orally bioavailable inhibitor of PARP-1 and PARP-2 (potency ≤5nM in vitro). ABT-888 does not inhibit other NAD-binding enzymes and has minimal CYP450 inhibition and induction. ABT-888 increases tumor growth delay resulting from radiation and DNA-damaging agents. It shows broad spectrum of chemoand radiopotentiation. The ability to potentiate temozolomide (TMZ) and develop a...

متن کامل

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O-methylguanine- DNA methyltransferase activity

The poly(ADP-ribose) polymerase (PARP) inhibitor ABT888 potentiates the antitumor activity of temozolomide (TMZ). TMZ resistance results from increased O-methylguanine-DNA methyltransferase (MGMT) activity and from mismatch repair (MMR) system mutations. We evaluated the relative importance of MGMT activity, MMR deficiency, nonhomologous end joining (NHEJ), and PARP activity in ABT-888 potentia...

متن کامل

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

A phase I trial of ABT-888 (veliparib), a PARP inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was carried out to determine maximum tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of the combination in patients with refractory solid tumors and lymphomas. Varying schedules and doses of intravenous topotecan in combination with ABT-888 (10 mg) admi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Biochemistry

دوره 49 6  شماره 

صفحات  -

تاریخ انتشار 2010